Therefore, it can be postulated that Raplink-1, by inhibiting the activation of NF-κB, MAPKs, and mTOR pathways (Figure 2, Figure 3 and Figure 4), can be a potential drug candidate against atherosclerosis and IAs. This evidence concerns the gene MTOR and atherosclerosis.